Cefepime/Zidebactam - Wockhardt
Alternative Names: WCK-5222; Zaynich; Zidebactam/cefepime intravenous - WockhardtLatest Information Update: 15 May 2025
At a glance
- Originator Wockhardt
- Developer IQVIA; Wockhardt
- Class Antibacterials; Azabicyclo compounds; Cephalosporins; Piperidines; Small molecules; Sulfoxides; Urinary anti-infective agents
- Mechanism of Action Beta lactamase inhibitors; Cell wall inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Gram-negative infections; Urinary tract infections
Most Recent Events
- 01 Apr 2025 The US FDA provides compassionate use approvals in the form of individual patient-specific expanded-access
- 31 Jan 2025 Wockhardt announces intention to submit New Drug Application with the US FDA and marketingauthorization application (MAA) with EMA for Gram-negative infections
- 31 Jan 2025 Efficacy and safety data from the phase III ENHANCE 1 trial in Gram-negative infections released by Wockhard